Prednisolone	B:C0032950
is	O
associated	O
with	O
a	O
worse	O
lipid	I:C0740400
profile	I:C0740400
than	O
hydrocortisone	O
in	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
.	O

Prednisolone	O
is	O
associated	O
with	O
a	O
worse	B:C0740400
lipid	I:C0740400
profile	I:C0740400
than	O
hydrocortisone	O
in	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
.	O

Prednisolone	O
is	O
associated	O
with	O
a	O
worse	O
lipid	I:C0740400
profile	I:C0740400
than	O
hydrocortisone	B:C0020268
in	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
.	O

Prednisolone	O
is	O
associated	O
with	O
a	O
worse	O
lipid	I:C0740400
profile	I:C0740400
than	O
hydrocortisone	O
in	O
patients	O
with	O
adrenal	B:C0001623
insufficiency	I:C0001623
.	O

Prednisolone	B:C0032950
is	O
used	O
as	O
glucocorticoid	O
replacement	O
therapy	I:C0279033
for	O
adrenal	O
insufficiency	I:C0001623
(	O
adrenal	O
insufficiency	I:C0001623
)	O
.	O

Prednisolone	O
is	O
used	O
as	O
glucocorticoid	B:C0017710
replacement	O
therapy	I:C0279033
for	O
adrenal	O
insufficiency	I:C0001623
(	O
adrenal	O
insufficiency	I:C0001623
)	O
.	O

Prednisolone	O
is	O
used	O
as	O
glucocorticoid	O
replacement	B:C0279033
therapy	I:C0279033
for	O
adrenal	O
insufficiency	I:C0001623
(	O
adrenal	O
insufficiency	I:C0001623
)	O
.	O

Prednisolone	O
is	O
used	O
as	O
glucocorticoid	O
replacement	O
therapy	I:C0279033
for	O
adrenal	B:C0001623
insufficiency	I:C0001623
(	O
adrenal	O
insufficiency	I:C0001623
)	O
.	O

Prednisolone	O
is	O
used	O
as	O
glucocorticoid	O
replacement	O
therapy	I:C0279033
for	O
adrenal	O
insufficiency	I:C0001623
(	O
adrenal	B:C0001623
insufficiency	I:C0001623
)	O
.	O

Recent	O
data	O
indicate	O
that	O
its	O
use	O
in	O
adrenal	B:C0001623
insufficiency	I:C0001623
is	O
associated	O
with	O
low	O
bone	O
mineral	I:C0005938
density	I:C0005938
.	O

Recent	O
data	O
indicate	O
that	O
its	O
use	O
in	O
adrenal	O
insufficiency	I:C0001623
is	O
associated	O
with	O
low	O
bone	B:C0005938
mineral	I:C0005938
density	I:C0005938
.	O

Data	O
on	O
risk	B:C0035648
factors	I:C0035648
for	O
cardiovascular	O
disease	I:C0007222
in	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
treated	O
with	O
prednisolone	O
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	O
of	O
excess	O
mortality	O
.	O

Data	O
on	O
risk	O
factors	I:C0035648
for	O
cardiovascular	B:C0007222
disease	I:C0007222
in	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
treated	O
with	O
prednisolone	O
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	O
of	O
excess	O
mortality	O
.	O

Data	O
on	O
risk	O
factors	I:C0035648
for	O
cardiovascular	O
disease	I:C0007222
in	O
patients	O
with	O
adrenal	B:C0001623
insufficiency	I:C0001623
treated	O
with	O
prednisolone	O
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	O
of	O
excess	O
mortality	O
.	O

Data	O
on	O
risk	O
factors	I:C0035648
for	O
cardiovascular	O
disease	I:C0007222
in	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
treated	O
with	O
prednisolone	B:C0032950
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	O
of	O
excess	O
mortality	O
.	O

Data	O
on	O
risk	O
factors	I:C0035648
for	O
cardiovascular	O
disease	I:C0007222
in	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
treated	O
with	O
prednisolone	O
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	B:C0007465
of	O
excess	O
mortality	O
.	O

We	O
aimed	O
to	O
address	O
this	O
question	O
using	O
real	O
-	O
world	O
data	O
from	O
the	O
European	B:C0282574
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
(	O
European	O
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
)	O
.	O

We	O
aimed	O
to	O
address	O
this	O
question	O
using	O
real	O
-	O
world	O
data	O
from	O
the	O
European	O
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
(	O
European	B:C0282574
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
)	O
.	O

European	B:C0282574
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
,	O
comprising	O
of	O
19	O
centres	O
across	O
Germany	O
,	O
the	O
Netherlands	O
,	O
Sweden	O
and	O
the	O
UK	O
,	O
commenced	O
enrolling	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
in	O
August	O
2012	O
.	O

European	O
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
,	O
comprising	O
of	O
19	O
centres	B:C0475309
across	O
Germany	O
,	O
the	O
Netherlands	O
,	O
Sweden	O
and	O
the	O
UK	O
,	O
commenced	O
enrolling	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
in	O
August	O
2012	O
.	O

European	O
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
,	O
comprising	O
of	O
19	O
centres	O
across	O
Germany	B:C0017480
,	O
the	O
Netherlands	O
,	O
Sweden	O
and	O
the	O
UK	O
,	O
commenced	O
enrolling	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
in	O
August	O
2012	O
.	O

European	O
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
,	O
comprising	O
of	O
19	O
centres	O
across	O
Germany	O
,	O
the	O
Netherlands	B:C0027778
,	O
Sweden	O
and	O
the	O
UK	O
,	O
commenced	O
enrolling	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
in	O
August	O
2012	O
.	O

European	O
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
,	O
comprising	O
of	O
19	O
centres	O
across	O
Germany	O
,	O
the	O
Netherlands	O
,	O
Sweden	B:C0038995
and	O
the	O
UK	O
,	O
commenced	O
enrolling	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
in	O
August	O
2012	O
.	O

European	O
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
,	O
comprising	O
of	O
19	O
centres	O
across	O
Germany	O
,	O
the	O
Netherlands	O
,	O
Sweden	O
and	O
the	O
UK	B:C0041700
,	O
commenced	O
enrolling	O
patients	O
with	O
adrenal	O
insufficiency	I:C0001623
in	O
August	O
2012	O
.	O

European	O
Adrenal	I:C0282574
Insufficiency	I:C0282574
Registry	I:C0282574
,	O
comprising	O
of	O
19	O
centres	O
across	O
Germany	O
,	O
the	O
Netherlands	O
,	O
Sweden	O
and	O
the	O
UK	O
,	O
commenced	O
enrolling	O
patients	O
with	O
adrenal	B:C0001623
insufficiency	I:C0001623
in	O
August	O
2012	O
.	O

Patients	O
receiving	O
prednisolone	B:C0032950
(	O
3	O
-	O
6	O
mg/day	O
,	O
n	O
=	O
50	O
)	O
or	O
hydrocortisone	O
(	O
15	O
-	O
30	O
mg/day	O
,	O
n	O
=	O
909	O
)	O
were	O
identified	O
and	O
grouped	O
at	O
a	O
ratio	O
of	O
1:3	O
(	O
prednisolone	O
:	O
hydrocortisone	O
)	O
by	O
matching	O
for	O
gender	O
,	O
age	O
,	O
duration	O
and	O
type	O
of	I:C0457464
disease	I:C0457464
.	O

Patients	O
receiving	O
prednisolone	O
(	O
3	O
-	O
6	O
mg/day	O
,	O
n	O
=	O
50	O
)	O
or	O
hydrocortisone	B:C0020268
(	O
15	O
-	O
30	O
mg/day	O
,	O
n	O
=	O
909	O
)	O
were	O
identified	O
and	O
grouped	O
at	O
a	O
ratio	O
of	O
1:3	O
(	O
prednisolone	O
:	O
hydrocortisone	O
)	O
by	O
matching	O
for	O
gender	O
,	O
age	O
,	O
duration	O
and	O
type	O
of	I:C0457464
disease	I:C0457464
.	O

Patients	O
receiving	O
prednisolone	O
(	O
3	O
-	O
6	O
mg/day	O
,	O
n	O
=	O
50	O
)	O
or	O
hydrocortisone	O
(	O
15	O
-	O
30	O
mg/day	O
,	O
n	O
=	O
909	O
)	O
were	O
identified	O
and	O
grouped	B:C0439745
at	O
a	O
ratio	O
of	O
1:3	O
(	O
prednisolone	O
:	O
hydrocortisone	O
)	O
by	O
matching	O
for	O
gender	O
,	O
age	O
,	O
duration	O
and	O
type	O
of	I:C0457464
disease	I:C0457464
.	O

Patients	O
receiving	O
prednisolone	O
(	O
3	O
-	O
6	O
mg/day	O
,	O
n	O
=	O
50	O
)	O
or	O
hydrocortisone	O
(	O
15	O
-	O
30	O
mg/day	O
,	O
n	O
=	O
909	O
)	O
were	O
identified	O
and	O
grouped	O
at	O
a	O
ratio	O
of	O
1:3	O
(	O
prednisolone	B:C0032950
:	O
hydrocortisone	O
)	O
by	O
matching	O
for	O
gender	O
,	O
age	O
,	O
duration	O
and	O
type	O
of	I:C0457464
disease	I:C0457464
.	O

Patients	O
receiving	O
prednisolone	O
(	O
3	O
-	O
6	O
mg/day	O
,	O
n	O
=	O
50	O
)	O
or	O
hydrocortisone	O
(	O
15	O
-	O
30	O
mg/day	O
,	O
n	O
=	O
909	O
)	O
were	O
identified	O
and	O
grouped	O
at	O
a	O
ratio	O
of	O
1:3	O
(	O
prednisolone	O
:	O
hydrocortisone	B:C0020268
)	O
by	O
matching	O
for	O
gender	O
,	O
age	O
,	O
duration	O
and	O
type	O
of	I:C0457464
disease	I:C0457464
.	O

Patients	O
receiving	O
prednisolone	O
(	O
3	O
-	O
6	O
mg/day	O
,	O
n	O
=	O
50	O
)	O
or	O
hydrocortisone	O
(	O
15	O
-	O
30	O
mg/day	O
,	O
n	O
=	O
909	O
)	O
were	O
identified	O
and	O
grouped	O
at	O
a	O
ratio	O
of	O
1:3	O
(	O
prednisolone	O
:	O
hydrocortisone	O
)	O
by	O
matching	O
for	O
gender	O
,	O
age	O
,	O
duration	O
and	O
type	B:C0457464
of	I:C0457464
disease	I:C0457464
.	O

Data	O
from	O
baseline	O
and	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
visits	O
were	O
analysed	O
.	O

Data	O
from	O
baseline	O
and	O
follow	O
-	I:C1522577
up	I:C1522577
visits	B:C1512346
were	O
analysed	O
.	O

Data	O
from	O
patients	O
with	O
congenital	B:C0001627
adrenal	I:C0001627
hyperplasia	I:C0001627
were	O
excluded	O
.	O

Significantly	O
higher	O
mean	O
±	O
s.d.	O
total	O
(	O
6.3	O
±	O
1.6	O
vs	O
5.4	O
±	O
1.1	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.003	O
)	O
and	O
low	B:C0023824
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
(	I:C0023824
LDL	I:C0023824
)	I:C0023824
cholesterol	I:C0023824
levels	O
(	O
3.9	O
±	O
1.4	O
vs	O
3.2	O
±	O
1.0	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.013	O
)	O
were	O
identified	O
in	O
47	O
patients	O
on	O
prednisolone	O
vs	O
141	O
receiving	O
hydrocortisone	O
at	O
baseline	O
and	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.006	O
,	O
respectively	O
)	O
.	O

Significantly	O
higher	O
mean	O
±	O
s.d.	O
total	O
(	O
6.3	O
±	O
1.6	O
vs	O
5.4	O
±	O
1.1	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.003	O
)	O
and	O
low	O
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
(	I:C0023824
LDL	I:C0023824
)	I:C0023824
cholesterol	I:C0023824
levels	O
(	O
3.9	O
±	O
1.4	O
vs	O
3.2	O
±	O
1.0	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.013	O
)	O
were	O
identified	O
in	O
47	O
patients	O
on	O
prednisolone	B:C0032950
vs	O
141	O
receiving	O
hydrocortisone	O
at	O
baseline	O
and	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.006	O
,	O
respectively	O
)	O
.	O

Significantly	O
higher	O
mean	O
±	O
s.d.	O
total	O
(	O
6.3	O
±	O
1.6	O
vs	O
5.4	O
±	O
1.1	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.003	O
)	O
and	O
low	O
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
(	I:C0023824
LDL	I:C0023824
)	I:C0023824
cholesterol	I:C0023824
levels	O
(	O
3.9	O
±	O
1.4	O
vs	O
3.2	O
±	O
1.0	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.013	O
)	O
were	O
identified	O
in	O
47	O
patients	O
on	O
prednisolone	O
vs	O
141	O
receiving	O
hydrocortisone	B:C0020268
at	O
baseline	O
and	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.006	O
,	O
respectively	O
)	O
.	O

Significantly	O
higher	O
mean	O
±	O
s.d.	O
total	O
(	O
6.3	O
±	O
1.6	O
vs	O
5.4	O
±	O
1.1	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.003	O
)	O
and	O
low	O
-	I:C0023824
density	I:C0023824
lipoprotein	I:C0023824
(	I:C0023824
LDL	I:C0023824
)	I:C0023824
cholesterol	I:C0023824
levels	O
(	O
3.9	O
±	O
1.4	O
vs	O
3.2	O
±	O
1.0	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.013	O
)	O
were	O
identified	O
in	O
47	O
patients	O
on	O
prednisolone	O
vs	O
141	O
receiving	O
hydrocortisone	O
at	O
baseline	O
and	O
at	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.006	O
,	O
respectively	O
)	O
.	O

HbA1c	B:C0019018
,	O
high	O
-	I:C0023821
density	I:C0023821
lipoprotein	I:C0023821
and	O
triglyceride	O
levels	I:C0428475
,	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
systolic	O
and	O
diastolic	O
blood	I:C0235222
pressure	I:C0235222
and	O
waist	O
circumference	I:C0455829
were	O
not	O
significantly	O
different	O
.	O

HbA1c	O
,	O
high	B:C0023821
-	I:C0023821
density	I:C0023821
lipoprotein	I:C0023821
and	O
triglyceride	O
levels	I:C0428475
,	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
systolic	O
and	O
diastolic	O
blood	I:C0235222
pressure	I:C0235222
and	O
waist	O
circumference	I:C0455829
were	O
not	O
significantly	O
different	O
.	O

HbA1c	O
,	O
high	O
-	I:C0023821
density	I:C0023821
lipoprotein	I:C0023821
and	O
triglyceride	B:C0428475
levels	I:C0428475
,	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
systolic	O
and	O
diastolic	O
blood	I:C0235222
pressure	I:C0235222
and	O
waist	O
circumference	I:C0455829
were	O
not	O
significantly	O
different	O
.	O

HbA1c	O
,	O
high	O
-	I:C0023821
density	I:C0023821
lipoprotein	I:C0023821
and	O
triglyceride	O
levels	I:C0428475
,	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
,	O
systolic	O
and	O
diastolic	O
blood	I:C0235222
pressure	I:C0235222
and	O
waist	O
circumference	I:C0455829
were	O
not	O
significantly	O
different	O
.	O

HbA1c	O
,	O
high	O
-	I:C0023821
density	I:C0023821
lipoprotein	I:C0023821
and	O
triglyceride	O
levels	I:C0428475
,	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
systolic	B:C0221155
and	O
diastolic	O
blood	I:C0235222
pressure	I:C0235222
and	O
waist	O
circumference	I:C0455829
were	O
not	O
significantly	O
different	O
.	O

HbA1c	O
,	O
high	O
-	I:C0023821
density	I:C0023821
lipoprotein	I:C0023821
and	O
triglyceride	O
levels	I:C0428475
,	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
systolic	O
and	O
diastolic	B:C0235222
blood	I:C0235222
pressure	I:C0235222
and	O
waist	O
circumference	I:C0455829
were	O
not	O
significantly	O
different	O
.	O

HbA1c	O
,	O
high	O
-	I:C0023821
density	I:C0023821
lipoprotein	I:C0023821
and	O
triglyceride	O
levels	I:C0428475
,	O
body	O
mass	I:C1305855
index	I:C1305855
,	O
systolic	O
and	O
diastolic	O
blood	I:C0235222
pressure	I:C0235222
and	O
waist	B:C0455829
circumference	I:C0455829
were	O
not	O
significantly	O
different	O
.	O

This	O
is	O
the	O
first	O
matched	O
analysis	B:C0936012
of	O
its	O
kind	O
.	O

Significantly	O
higher	O
LDL	B:C0428473
levels	I:C0428473
in	O
patients	O
receiving	O
prednisolone	O
relative	O
to	O
hydrocortisone	O
could	O
predict	O
a	O
higher	O
relative	O
risk	O
of	O
cardiovascular	O
disease	I:C0007222
in	O
the	O
former	O
group	O
.	O

Significantly	O
higher	O
LDL	O
levels	I:C0428473
in	O
patients	O
receiving	O
prednisolone	B:C0032950
relative	O
to	O
hydrocortisone	O
could	O
predict	O
a	O
higher	O
relative	O
risk	O
of	O
cardiovascular	O
disease	I:C0007222
in	O
the	O
former	O
group	O
.	O

Significantly	O
higher	O
LDL	O
levels	I:C0428473
in	O
patients	O
receiving	O
prednisolone	O
relative	O
to	O
hydrocortisone	B:C0020268
could	O
predict	O
a	O
higher	O
relative	O
risk	O
of	O
cardiovascular	O
disease	I:C0007222
in	O
the	O
former	O
group	O
.	O

Significantly	O
higher	O
LDL	O
levels	I:C0428473
in	O
patients	O
receiving	O
prednisolone	O
relative	O
to	O
hydrocortisone	O
could	O
predict	O
a	O
higher	O
relative	O
risk	O
of	O
cardiovascular	B:C0007222
disease	I:C0007222
in	O
the	O
former	O
group	O
.	O

